GTES:NYSEGates Industrial Corporation plc Analysis
Data as of 2026-04-07 - not real-time
$22.50
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Gates Industrial (GTES) posted a Q4 earnings beat, with revenue up 3.2% YoY to $856.2 M and non‑GAAP EPS of $0.38 surpassing consensus. The stock trades at $22.50, comfortably above its DCF‑derived fair value of $14.09 and with a forward P/E of 12.1 versus a trailing P/E of 23.4, indicating the market is pricing in strong earnings growth. However, the company’s margins remain modest (gross 40.5%, operating 16%) and its debt‑to‑equity sits at 64.8%, tempering the upside narrative.
Technically, GTES sits below its 20‑day (22.82) and 50‑day (24.67) SMAs, while the RSI of 44 signals a neutral stance. A bullish MACD crossover (line above signal) and a price near the identified support of $20.88 suggest short‑term resilience, but high 30‑day volatility (≈47%) and a beta of 1.43 point to pronounced price swings. Analyst consensus remains a “Buy” with a median target of $31.5, yet the current valuation appears stretched relative to intrinsic estimates.
Technically, GTES sits below its 20‑day (22.82) and 50‑day (24.67) SMAs, while the RSI of 44 signals a neutral stance. A bullish MACD crossover (line above signal) and a price near the identified support of $20.88 suggest short‑term resilience, but high 30‑day volatility (≈47%) and a beta of 1.43 point to pronounced price swings. Analyst consensus remains a “Buy” with a median target of $31.5, yet the current valuation appears stretched relative to intrinsic estimates.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Q4 earnings beat and modest revenue growth
- Bullish MACD crossover near support level
- Analyst consensus remains positive (Buy)
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Current price above DCF fair value, indicating overvaluation
- Elevated volatility and beta suggesting price swings
- Margin compression and high debt‑to‑equity ratio
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Steady but low single‑digit revenue growth
- Absence of dividend reduces income appeal
- Global exposure introduces medium geographic and regulatory risk
Key Metrics & Analysis
Financial Health
Revenue Growth3.20%
Profit Margin7.30%
P/E Ratio23.4
ROE7.88%
ROA4.74%
Debt/Equity64.81
P/B Ratio1.7
Op. Cash Flow$478.1M
Free Cash Flow$338.4M
Industry P/E29.7
Technical Analysis
TrendNeutral
RSI44.6
Support$20.88
Resistance$24.90
MA 20$22.82
MA 50$24.67
MA 200$23.99
MACDBullish
VolumeDecreasing
Fear & Greed Index76.57
Valuation
Fair Value$14.09
Target Price$31.67
Upside/Downside40.74%
GradeOvervalued
TypeValue
Risk Assessment
Beta1.43
Volatility47.08%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.